January 24, 2020 Drug Utilization Review Board
»
1. Call to order
1. Call to order
»
2. Approval of minutes from October 25, 2019 (vote required)
2. Approval of minutes from October 25, 2019 (vote required)
»
3. Texas Insurance Code chapter 1360, subchapter E-1, as adopted by HB 1584, 86th Leg., R.S. (2019) update – coverage of prescription drugs for stage four advanced, metastatic cancer and associated conditions
3. Texas Insurance Code chapter 1360, subchapter E-1, as adopted by HB 1584, 86th Leg., R.S. (2019) update – coverage of prescription drugs for stage four advanced, metastatic cancer and associated conditions
»
4. New business:
Public comment on drug classes to be reviewed for the Medicaid preferred drug list (PDL): » - a. Acne agents, oral b. Acne agents, topical c. Analgesics, narcotics long d. Analgesics, narcotics short e. Angiotensin modulator combinations f. Angiotensin modulators g. Antimigraine agents, other h. Antimigraine agents, triptans i. Bladder relaxant preparations j. Glucagon agents k. H. Pylori treatment l. Immunomodulators, atopic dermatitis m. Intranasal rhinitis agents n. Movement disorders o. Neuropathic pain p. Phosphate binders q. Platelet aggregation inhibitors r. Progestins for cachexia s. Proton pump inhibitors t. Smoking cessation u. Stimulants and related agents
4. New business: Public comment on drug classes to be reviewed for the Medicaid preferred drug list (PDL): »
a. Acne agents, oral b. Acne agents, topical
c. Analgesics, narcotics long
d. Analgesics, narcotics short
e. Angiotensin modulator combinations
f. Angiotensin modulators
g. Antimigraine agents, other
h. Antimigraine agents, triptans
i. Bladder relaxant preparations
j. Glucagon agents
k. H. Pylori treatment
l. Immunomodulators, atopic dermatitis
m. Intranasal rhinitis agents
n. Movement disorders
o. Neuropathic pain
p. Phosphate binders
q. Platelet aggregation inhibitors
r. Progestins for cachexia
s. Proton pump inhibitors
t. Smoking cessation
u. Stimulants and related agents
»
5. Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL: » - a. Nourianz (oral) / Antiparkinson's agents b. Proair Digihaler (inhalation) / Bronchodilators, beta agonist c. Duaklir Pressair (inhalation) / chronic obstructive pulmonary disease agents d. Rybelsus (oral) / Hypoglycemics, incretin mimetics/enhancers e. Fiasp Penfill (subcutaneous) / Hypoglycemics, insulin and related agents f. Xembify (subcutaneous) / immune globulins g. Relafen DS (oral) / nonsteroidal anti-inflammatory drugs
5. Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL: »
a. Nourianz (oral) / Antiparkinson's agents b. Proair Digihaler (inhalation) / Bronchodilators, beta agonist
c. Duaklir Pressair (inhalation) / chronic obstructive pulmonary disease agents
d. Rybelsus (oral) / Hypoglycemics, incretin mimetics/enhancers
e. Fiasp Penfill (subcutaneous) / Hypoglycemics, insulin and related agents
f. Xembify (subcutaneous) / immune globulins
g. Relafen DS (oral) / nonsteroidal anti-inflammatory drugs
»
6. Therapeutic and clinical drug reviews and updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
6. Therapeutic and clinical drug reviews and updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
»
7. Executive work session
Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the Drug Utilization Review (DUR) Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
7. Executive work session Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the Drug Utilization Review (DUR) Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
»
8. Announcements of drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
8. Announcements of drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
»
9. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required) » - a. Fentanyl (inhalation/oral transdermal) b. Gabapentin c. Hydrocodone Bitrate/Hydrocodone Polistirex d. Ivacaftor (Kalydeco®) and Combination Therapy e. Topical Calcineurin Inhibitors- Pimecrolimus (Elidel®), Tacrolimus (Protopic®) f. Tramadol (Ultram®)
9. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required) »
a. Fentanyl (inhalation/oral transdermal) b. Gabapentin
c. Hydrocodone Bitrate/Hydrocodone Polistirex
d. Ivacaftor (Kalydeco®) and Combination Therapy
e. Topical Calcineurin Inhibitors- Pimecrolimus (Elidel®), Tacrolimus (Protopic®)
f. Tramadol (Ultram®)
»
10. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC » - a. Report on recent retrospective DUR interventions: i. Anticonvulsant drug use evaluation ii. Influenza prevention iii. Cough and cold remedies b. Report on recent retrospective DUR intervention outcomes: i. Second generation antipsychotics in youth ii. Proton pump inhibitors iii. Appropriate use of antibiotics c. Retrospective DUR proposals (vote required) i. Diabetes disease management ii. Monitoring of psychotropic drugs in youth iii. Postpartum depression
10. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC »
a. Report on recent retrospective DUR interventions: i. Anticonvulsant drug use evaluation
ii. Influenza prevention
iii. Cough and cold remedies
b. Report on recent retrospective DUR intervention outcomes:
i. Second generation antipsychotics in youth
ii. Proton pump inhibitors
iii. Appropriate use of antibiotics
c. Retrospective DUR proposals (vote required)
i. Diabetes disease management
ii. Monitoring of psychotropic drugs in youth
iii. Postpartum depression
»
11. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required) » - a. Cystic Fibrosis Agents – additional of Trikafta™ criteria b. Inhaled antibiotics – revision c. Oxbryta™ – new criteria d. Pulmonary arterial hypertension (PAH) agents – addition of oral PAH agents
11. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required) »
a. Cystic Fibrosis Agents – additional of Trikafta™ criteria b. Inhaled antibiotics – revision
c. Oxbryta™ – new criteria
d. Pulmonary arterial hypertension (PAH) agents – addition of oral PAH agents
»
Items 12 & 13 » - 12. Next meeting date: April 24, 2020 13. Adjourn
Items 12 & 13 »
12. Next meeting date: April 24, 2020 13. Adjourn
